Patients with higher level solid tumors with no standard treatment available were qualified to receive study participation. Inclusion criteria were life expectancy of at least 12 wk, WHO performance position of 0 to 2, age of 18 y or older, and adequate bone marrow, liver, and renal function. Exclusion criteria were history of cardiac infection, peptide calculator history of HIV, hepatitis B, or hepatitis C infection, active scientifically serious infection, serious nonhealing wound, ulcer, or bone fracture, characteristic metastatic brain or meningeal tumors, pregnancy or breast feeding, therapy with any anticancer adviser or investigational drug 4 wk before the very first dose, antiangiogenic therapies/VEGFR 2 inhibitors before application. Along side it study was performed on people which were treated in the Leiden University Medical Center. The analysis protocol was approved by the Medical Ethical Committee of the Leiden University Medical Center. All clients gave written angiogenic activity informed consent. Telatinib is an orally active, little molecule inhibitor of the VEGFR 2, VEGFR 3 tyrosine kinases, and the growth factors receptors platelet derived growth factor receptor a and c Kit. Telatinib was continuously given once daily or twice daily in an verbal formulation as solution or pill. Patients were divided in to cohorts with increasing doses. Therapy continued until progressive illness, inappropriate toxicity, death, agreement withdrawal, or withdrawal from study at the discretion of the investigator. Telatinib was supplied by Bayer Pharmaceuticals Corporation. We examined body pressure, vascular function, and structure variables at baseline, and after 5 wk of therapy, in addition to regular examination of variables for efficacy, pharmacokinetics, Metastasis and safety. Blood force, flow mediated dilation, nitroglycerin mediated dilation, aortic pulse wave velocity, skin body flux with laser doppler flow, and capillary density with sidestream dim field imaging were evaluated at baseline and after 5 wk of therapy with telatinib. All measurements were done by the exact same experienced examiner, each morning, in a quiet, temperature controlled room. Peripheral blood pressure measurements were also done at every visit to the outpatient clinic. Peripheral blood pressure. Peripheral blood pressure measurements at baseline and at the 5 wk visit were completed after 15 min rest, testing thrice in a position with 5 min intervals, having an automated device with the cuff placed at the brachial artery. For statistical fgfr1 inhibitor analysis, we used the mean of three consecutive measurements. Peripheral blood pressure measurements at the regular trip to the outpatient clinic were completed by the treating physician, having an aneroid sphygmomanometer with the auscultatory method. Central blood pressure. Program tonometry of the brachial and external carotid artery was done. The mean of the three peripheral blood pressure measurements was used to estimate central aortic pressure. Aortic pulse wave velocity.